Guidance offered for managing pain in patients with cancer and OUD

The appropriateness of strategies for managing cancer pain in individuals with advanced cancer and opioid use disorder (OUD) is addressed in a consensus statement published online Dec. 28 in JAMA Network Open.

Jessica S. Merlin, M.D., Ph.D., from the University of Pittsburgh, and colleagues developed a consensus statement on the appropriateness of strategies for managing cancer pain in individuals with co-occurring advanced cancer and OUD. A total of 120 experts in palliative care, addiction, or both participated in a three-round modified Delphi process.

The researchers deemed it appropriate to continue buprenorphine-naloxone with three times-daily dosing for patients with OUD taking buprenorphine-naloxone. For patients with a prognosis of weeks to months, continuing buprenorphine-naloxone and adding a full-agonist opioid was deemed to be appropriate; appropriateness was uncertain for those with a prognosis of months to years. It was deemed appropriate to take over prescribing for a patient with OUD taking methadone dispensed at a methadone clinic and to dose two or three times daily. For patients with a diagnosis of weeks to months, continuing methadone daily while adding another full-agonist opioid was deemed appropriate, while the appropriateness was uncertain for those with a prognosis of months to years.

Source: Read Full Article